Iranian clinical trials: An analysis of registered trials in International Clinical Trial Registry Platform (ICTRP)

Feizabadi, Mansoureh; Fahimnia, Fatima; Jarrahi, Alireza Mosavi; Naghshineh, Nader; Tofighi, Shahram

doi:10.1111/jebm.12248

Cited by 18 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, lower respiratory infection, low back and neck pain, sense organ diseases, skin diseases, and ischemic heart diseases are the most important burden of diseases in Peru . There was no correlation between RCTs specialty and main burden diseases, similar reported in Iran . Then, we suggest encouraging Peruvian research institutions and hospitals to develop and implement financial support to RCTs execution, in order to attend the main diseases in the country.…”

Section: Discussionmentioning

confidence: 64%

“…28 There was no correlation between RCTs specialty and main burden diseases, similar reported in Iran. 29 Then, we suggest encouraging Peruvian research institutions and hospitals to develop and implement financial support to RCTs execution, in order to attend the main diseases in the country.…”

Section: Ranakawa Et Al Describe That Most Rcts Registered In Sri Lanmentioning

confidence: 99%

See 1 more Smart Citation

Twenty‐two years’ experience registering trials in a low‐middle income country: The Peruvian Clinical Trial Registry

Alarcón-Ruiz

Roque‐Roque

Heredia

et al. 2019

J Evidence Based Medicine

View full text Add to dashboard Cite

Aim This study analyzes the quantitative and qualitative evolution of the Peruvian Clinical Trial Registry during the last 22 years. Methods Following a cross‐sectional design, we reviewed all clinical trials registered at the Peruvian Clinical Trial Registry during 1995‐2017. We downloaded and extracted all registries on 31 March 2018. We summarized qualitative variables and quantitative variables. Also, we performed trends analysis of the records by year, clinical phase, institutional review board, and children's participation. Results The Peruvian Clinical Trial Registry recorded 1748 clinical trials during 1995‐2017. Considering World Health Organization 20‐standard descriptors as the standard, the registry suitably recorded four of them in 1995 and 19 since 2013. There was a meaningful change in the trend of the registries, showing a significant upward registry trend until 2008 and a significant downward registry trend since then. This trend could be influenced by new regulation in clinical trials registry. Several trials had incomplete entries for different studied variables. Most of the clinical trials (82%) included male and female participants, and only 14% included children. Oncological disorders were the diseases most frequently investigated (20%). Most of clinical trials were registered by pharmaceutical companies. A few institutional review boards evaluated most of the clinical trials. Conclusion The registration of clinical trials in Peru has improved quantitatively and qualitatively since it started, but its quantitative grow stopped in 2008. Since then, the number of registries has declined steadily. There is an influence of pharmaceutical companies in clinical trial registration.

show abstract

Section: Discussionmentioning

confidence: 64%

Section: Ranakawa Et Al Describe That Most Rcts Registered In Sri Lanmentioning

confidence: 99%

Twenty‐two years’ experience registering trials in a low‐middle income country: The Peruvian Clinical Trial Registry

Alarcón-Ruiz

Roque‐Roque

Heredia

et al. 2019

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

“…This also provides real-time guidance in preventing and controlling the spread of the pandemic and evaluating the trends of the pandemic and the effects of intervention measures. [ 8 ] COVID-19's “pandemic prevention and control” strategy is closely related to important measures to improve the transparency of clinical trials in terms of sharing original data of the subjects and standardized trial design, registration, and implementation. [ 9 , 10 ]…”

Section: Discussionmentioning

confidence: 99%

Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations

2020

View full text Add to dashboard Cite

Up-to-date information on the current progress made in the research and development to control the global COVID-19 pandemic is important. The study aimed to analyze the clinical trial characteristics and vaccine development progress of the new Coronavirus Disease 2019 (COVID-19) registered with the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP). A comprehensive search of COVID-19 clinical trials since the establishment of the ICTRP to June 11, 2020, was conducted to record and analyze relevant characteristics. Chi-Squared test was used to compare the statistical differences between different research types, interventions, and sources. A total of 3282 COVID-19 clinical trials in 17 clinical trial registration centers were registered with the WHO ICTRP. The main research sources for the present study were ClinicalTrials.gov and ChiCTR. There were significant differences in the parameters of study location ( P = .000), number of participants ( P = .000), study duration ( P = .001), research stage ( P = .000), randomization procedure ( P = .000), and blinding method ( P = .000) between the 2 registration sources. There were significant differences in all the parameters between different kinds of intervention methods. Hydroxychloroquine, plasma therapy, and Xiyanping injection were the high-frequency research drugs used. Ten different vaccine studies were registered under phases I-II. Amongst the studies researched, heterogeneity existed for various parameters. Differences in the type of study, interventions, and registration sources of the studies led to significant differences in certain parameters of the COVID-19 clinical trials. The statistics of high-frequency drugs and the progress of vaccine trials may provide an informative reference for the prevention and control of COVID-19.

show abstract

“…The study sponsor was classified according to the information on the organization's website. The primary sponsor is defined in the WHO ICTRP as the “organization which takes responsibility for the initiation, management, and/or financing of a clinical trial” [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

Research Priorities and Resource Allocation in the Investigation of New Drugs for Cancer in Least Developed Countries

Silva

Amato

Andrade

et al. 2018

Journal of Oncology

View full text Add to dashboard Cite

Cancer incidence has increased significantly in low- and middle-income countries. The priorities of international health research are not always aligned with the global burden of cancer. This study aims to analyze global tendencies in clinical trials in oncology and discuss research priorities and resource allocation in the investigation of new drugs for cancers that significantly affect the least developed countries. This was a retrospective and analytical study that included data collected from the World Health Organization's International Clinical Trials Registry Platform (ICTRP) in 2014. According to our results, there was a tendency for clinical trials involving breast and lung cancer to be conducted in countries with a lower level of economic development. On the other hand, cervical, stomach, and liver cancer, despite the significant burden that these place on middle- and low-income countries, were studied little among the countries selected. In conclusion, the organizations that most fund research to develop new drugs for cancer treatment continue to show little interest in prioritizing resources to fund research for certain types of cancer such as those of the cervix, stomach, and liver, which have a significant impact in low- and middle-income countries.

show abstract

Iranian clinical trials: An analysis of registered trials in International Clinical Trial Registry Platform (ICTRP)

Abstract: The results showed that, despite an increase in registration of clinical trials in Iran, most studies registered were conducted on diseases, which form only a small percentage of the total disease burden of the country.

Cited by 18 publications

References 15 publications

Twenty‐two years’ experience registering trials in a low‐middle income country: The Peruvian Clinical Trial Registry

Twenty‐two years’ experience registering trials in a low‐middle income country: The Peruvian Clinical Trial Registry

Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations

Research Priorities and Resource Allocation in the Investigation of New Drugs for Cancer in Least Developed Countries

Contact Info

Product

Resources

About